ARCHIVES

FDA Approval of Abraxane Sets Stage for Competition Between Taxane Drugs. Abraxane a Nanotechnology Drug? Sponsor Says Yes, FDA Says.

This article is from The Cancer Letter archive.

Vol. 31 No. 02 | January 14, 2005

Download PDF Visit The Full Archive

Related Articles

NCI, NHGRI Fund Two More Components of TCGA Project.

October 27, 2006

Study Finds Green Tea No Help In Advanced Prostate Cancer

March 28, 2003

Scope Of Panel’s Inquiry Outlined In Letter To Members

July 22, 1994

CCIRC Told Group Radiation Studies Cost $20,000 Per 25 Patients

March 14, 1980

Sixty CCOPs Could cost $16 Million; DCPC Staff Believes They Can Get It

October 10, 1986

Gene Patterns Predict Lymphoma Response To Treatment

June 28, 2002